QP 09 - Fewer Fractions, Greater Precision: Innovations in Prostate SBRT

Presentations

• 03:00pm - 03:05pm ET

  Introductions

  Speaker: Abhishek Solanki, MD, MS - Loyola University Medical Center, Maywood
• 03:05pm - 03:10pm ET

  Randomized Phase II Trial of Stereotactic Body (SBRT) vs. Conventional Fractionation (CF) Radiotherapy Boost for High-Risk Prostate Cancer: Biochemical Control Outcomes of the PBS Trial

  Speaker: Libby Ben-Zvi, - McMaster University, Hamilton
• 03:10pm - 03:15pm ET

  Five-Year Outcomes from a Prospective Trial of MR-Guided SBRT with Focal DIL Boost for Intermediate-Risk Prostate Cancer

  Speaker: Alexander Goglia, MD, PhD - Memorial Sloan Kettering Cancer Center, New York
• 03:15pm - 03:20pm ET

  The ART of SABR: A Randomized Phase II Trial of Near "Margin-less" Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer: Two vs. Five Fractions

  Speaker: Mark Waddle, MD - Mayo Clinic Rochester, Rochester
• 03:20pm - 03:25pm ET

  Results of a Phase 2 Trial of Prostate SBRT with Integrated Tumor Boost and Dose Reduction at Urethra, Bladder and Rectal Interfaces

  Speaker: Trevor Wilson, MD - University of Wisconsin, Madison
• 03:25pm - 03:30pm ET

  Phase II Study of Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost (SBRT-SIB) Delivered on an MR-LINAC for Intermediate and High Risk Prostate Cancer: 2 Year Outcomes

  Speaker: Emily Weg, MD - Weill Cornell Medicine, New York
• 03:30pm - 03:35pm ET

  MR-Linac Based Prostate SBRT with Simultaneous Integrated Boost to Dominant Index Lesions: Early Results of a Prospective Multicenter Phase II Trial

  Speaker: Magali Quivrin, MD - Centre Georges François LECLERC Anticancer Center, Dijon
• 03:35pm - 03:55pm ET

  Questions & Answers

  Speaker: Luca Valle, MD - UCLA Radiation Oncology, Los Angeles
• 03:55pm - 04:00pm ET

  Closing

  Speaker: Abhishek Solanki, MD, MS - Loyola University Medical Center, Maywood